In vivo Biodistribution and Clearance of Magnetic Iron Oxide Nanoparticles for Medical Applications
Julia Nowak-Jary,Beata Machnicka
DOI: https://doi.org/10.2147/IJN.S415063
IF: 7.033
2023-07-27
International Journal of Nanomedicine
Abstract:Julia Nowak-Jary, Beata Machnicka University of Zielona Gora, Faculty of Biological Sciences, Department of Biotechnology, Zielona Gora, 65-516, Poland Correspondence: Julia Nowak-Jary, Email Magnetic iron oxide nanoparticles (magnetite and maghemite) are intensively studied due to their broad potential applications in medical and biological sciences. Their unique properties, such as nanometric size, large specific surface area, and superparamagnetism, allow them to be used in targeted drug delivery and internal radiotherapy by targeting an external magnetic field. In addition, they are successfully used in magnetic resonance imaging (MRI), hyperthermia, and radiolabelling. The appropriate design of nanoparticles allows them to be delivered to the desired tissues and organs. The desired biodistribution of nanoparticles, eg, cancerous tumors, is increased using an external magnetic field. Thus, knowledge of the biodistribution of these nanoparticles is essential for medical applications. It allows for determining whether nanoparticles are captured by the desired organs or accumulated in other tissues, which may lead to potential toxicity. This review article presents the main organs where nanoparticles accumulate. The sites of their first uptake are usually the liver, spleen, and lymph nodes, but with the appropriate design of nanoparticles, they can also be accumulated in organs such as the lungs, heart, or brain. In addition, the review describes the factors affecting the biodistribution of nanoparticles, including their size, shape, surface charge, coating molecules, and route of administration. Modern techniques for determining nanoparticle accumulation sites and concentration in isolated tissues or the body in vivo are also presented. Graphical Keywords: magnetic nanoparticles, iron oxide nanoparticles, biodistribution, biodegradation Graphical Magnetic nanoparticles/iron oxide nanoparticles (MNPs/IONPs) (magnetite Fe 3 O 4 and maghemite γ-Fe 2 O 3 ) have been under intensive investigation since they show great potential for biomedical applications, such as tumors imaging (MRI), 1–3 radiolabelling and internal radiotherapy, 4 hyperthermia, 5,6 gene therapy, 7 biomolecules separation 8,9 and drug delivery. 9,10 Drug delivery is a vast field of MNPs applications as they possess a relatively large surface that enables binding and carrying other compounds, which can be directed using an external magnetic field to specific places in the body. 11 Additionally, nanoparticles depending on their size, can penetrate almost all tissues. Importantly, drugs immobilized on MNPs usually gain more beneficial properties, such as better solubility in water 12 and higher cytotoxicity to cancer cells. 13,14 The uniqueness of iron oxide nanoparticles lies in their ferromagnetic nature. They consist of areas of permanent magnetization (so-called magnetic domains), generating a magnetic field around them (like small magnets). Ferromagnets are ferromagnetic below the Curie temperature and paramagnetic above. Magnetization is changing the direction of magnetization in domains or the boundaries of domains. All elementary magnetic dipoles align with an external magnetic field at magnetic saturation. The external magnetic field can guide magnetite and maghemite nanoparticles to specific locations in the body. 15,16 In the case of magnetic-targeted drugs, such as anti-cancer drugs, this results in lower toxicity and lower doses. Ferromagnetism distinguishes MNPs from other types of nanoparticles used in medicine, such as gold (AuNPs), silver (AgNPs) nanoparticles, or polymer nanoparticles (PNPs). On the surface of AuNPs, electrons oscillate under the influence of light (surface plasmon resonance). AuNPs can scatter light intensely and are photostable, which makes these particles attractive imaging tools. 17 They are also used as contrast agents in computed tomography. 18 Among nanoparticles, AuNPs, and MNPs have also gained prominence as nanoradiopharmaceuticals for cancer imaging and therapy due to their biocompatibility, functionalization capabilities, and radiolabeling potential. 19–25 These targeted nanobrachytherapy approaches offer less invasiveness and improved radiation dose distribution compared to conventional treatments. Silver nanoparticles also show radiosensitizing properties. 26 Unfortunately, the main disadvantage of metallic nanoparticles is their non-biodegradability and toxicity. For example, the mice given 8 mg/kg AuNPs per body developed fatigue and a crooked spine, most of which died within three weeks. 27 In addition, Cho et al studied that PEGylated AuNPs (maximum dose 4.26 m -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology